

# PTPRG activates m6A methyltransferase VIRMA to block mitochondrial autophagy mediated neuronal death in Alzheimer's disease

Jiefeng Luo<sup>1#</sup>, Xiaohua Huang<sup>2#</sup>, Rongjie Li<sup>3#</sup>, Jieqiong Xie<sup>1#</sup>, Liechun Chen<sup>1</sup>, Chun Zou<sup>1</sup>, Zifei Pei<sup>3</sup>, Yingwei Mao<sup>4\*</sup>, Donghua Zou<sup>1\*</sup>

<sup>1</sup> Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530007, People's Republic of China

<sup>2</sup> Department of Neurology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi 533000, People's Republic of China

<sup>3</sup> Department of Neurology, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530022, People's Republic of China

<sup>4</sup> Department of Biology, Pennsylvania State University, University Park, PA, 16802, USA.

# These authors contributed equally to this work.

\*: Correspondence to

Yingwei Mao: [yzm1@psu.edu](mailto:yzm1@psu.edu); Donghua Zou: [zoudonghua@gxmu.edu.cn](mailto:zoudonghua@gxmu.edu.cn).

**Abstract:** In Alzheimer's disease (AD), neuronal death is one of the key pathology. However, the initiation of neuronal death in AD is far from clear, and new targets are urgently needed to develop effective therapeutic methods. This study analyzed sequencing data from single-cell RNAseq and spatialomics, and revealed the impact of global single-cell mapping and cell spatial distribution relationships in early stage of AD. We found that microglia subpopulation Mic\_PTPRG can anchor neurons based on ligand-receptor interaction pairs and cause ectopic expression of PTPRG in neurons during AD progression. PTPRG in neurons can bind and upregulate VIRMA expression, which in turn increases the level of m6A methylation, enhances PRKN transcript degradation and represses translation. Repressed PRKN expression blocks the clearance of damaged mitochondria in neurons, which in turn reprograms neuronal energy and nutrient metabolic pathways and leads to neuronal death during AD progression. This study elucidates novel mechanisms, by which the PTPRG-dependent microglia-synaptic modification may play a role in AD, providing a new scientific basis for potential therapeutic targets for AD.

**Keywords:** neuronal death ecotone, single-cell technology, spatial transcriptomics, mitochondrial

damage depletion, m6A methylation modification, energy and nutrient metabolism imbalance

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Introduction

Alzheimer's disease (AD), the main form of dementia in the elderly, is a progressive and irreversible neurodegenerative disease accompanied by the degeneration and neuronal death (1). The symptoms of AD usually begin with mild memory difficulties and gradually progress to cognitive impairment, language impairment and personality changes as the disease deteriorates (2). The long duration of the disease and the high rate of disability make the patients lose their ability to live independently in the late stages and require complete care from others, which brings a heavy burden to the society and families. In the last decades, studies have found that biological (e.g., aging, gender, weight, etc.), environmental (e.g., lifestyle, toxins, brain injury, etc.) and genetic (e.g., APP, PS1 and PS2 gene mutations in familial AD and susceptibility genetic polymorphisms in disseminated cases) factors play an important role in the pathogenesis of AD (3). Although these findings have greatly improved our understanding of AD, the underlying mechanisms of AD pathogenesis remain elusive, and current treatments can only target symptoms but not alter the disease process.

It is now generally accepted that extracellular aggregation of amyloid- $\beta$  (A $\beta$ ) plaques plays an important role in the pathogenesis of AD (4). In addition, intracellular neurofibrillary tangles (NFT), which consist of hyperphosphorylated TAU proteins, also play an important role in the pathogenesis of AD and are also the most prominent pathological process in neurons (5, 6). In the brain, neurons express a large number of molecules that protect them from inflammatory attacks and induce neurological dysfunction. However, neuronal death is present to various degrees in almost all AD patients (7), suggesting that the ecological niche of neuronal death - both excitatory and inhibitory neurons - may have different degrees of cell death. Notably, neurons are high-energy cells that depend primarily on mitochondria for ATP production and Ca<sup>2+</sup> homeostasis to maintain action potential (8), whereas mitochondria are highly dynamic organelles that regulate their morphology and distribution through constant division and fusion events (9, 10). Through this process, mitochondria respond to high energy demands and promote neuroprotective effects by eliminating defective mitochondrial components and preventing damage from reactive oxygen species during aging (11-13). However, mitochondrial dysfunction is commonly found in AD (14). Therefore, it is crucial to explore in depth the relationship between neuronal death and mitochondrial damage,

which not only helps to further elucidate the pathogenesis of AD, but also may provide potential novel therapeutic targets for the treatment of AD.

However, the human brain is an extremely complex tissue and ordinary research tools are no longer sufficient for our research needs. The recent popularity of single-cell technology and spatial histology has provided us with advanced technological conditions. Single-cell technology allows us to understand and explore diseases with a high-resolution perspective. Spatialomics is another research technology other than single-cell sequencing, which can reveal the influence of cell spatial distribution relationship on diseases by studying the relative position relationship of cells in tissue samples. Thus spatialomics compensates the shortcoming that single-cell sequencing technology cannot obtain information of cell spatial distribution. Currently, single-cell technology and spatial histology have been widely used in the study of brain development and AD. Ugomma C Eze et al. used single-cell techniques to characterize the major cell types of human brain development and the subpopulations of progenitor cells that form the basis of the human cerebral cortex (15). Sabina Kanton et al. used single-cell techniques to reveal dynamic gene regulation features of human brain development (16). Shun-Fat Lau et al. based on single-nucleus transcriptome analysis revealed dysregulation of AD vascular endothelial cells and neuroprotective glial cells (17). In addition, José Fernández Navarro et al. revealed genes associated with mitochondrial dysfunction and stress signaling in AD based on spatial transcriptomics (18).

Further exploration of the ecological niche of neuronal death in AD can help us understand how AD occurs and progresses, and eventually guide the development of new diagnostic and therapeutic strategies. To this end, this study analyzed single-cell RNA sequencing (scRNA-seq) data from AD brains as well as spatial transcriptomics data from AD mice. In contrast to previous studies, we provide new insights and molecular evidence for cellular communication at the single-cell transcriptome level combined with spatial transcriptomics in AD. In particular, microglia and neurons play a dominant role in the intercellular communication network in AD, revealing the development of AD by exploring the relationship between neuronal death and mitochondrial damage.

## **Materials and Methods**

### **Data source**

To study transcriptomic changes in various cell types during AD, we collected the following AD single-cell RNA sequencing (scRNAseq) datasets from the Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)) database: GSE138852 on the GPL18573 platform, GSE146639 on the GPL21697 platform, GSE147528, GSE157827, GSE163577, GSE174367 and GSE181279 on the GPL24676 platform, GSE160936 on the GPL20301 platform. In addition, there is a set of data from Hansruedi Mathys' group of professors (19). Samples for all data included tissue samples from prefrontal cortex, internal olfactory cortex, superior parietal lobe, superior frontal gyrus, caudal internal olfactory cortex, somatosensory cortex, hippocampus, superior frontal cortex, and peripheral blood mononuclear cells, involving a total of 85 AD samples and 83 control samples. In addition, spatial transcriptome data were obtained from GSE152506 on GPL19057 platform for mouse coronal slices including 3, 6, 12 and 18 month old AppNL-G-F KI mice (experimental group: n=6) and C57Bl/6J mice (control group: n=6).

### **Cell clusters and differentially expressed genes**

The Seurat package (20) was used for cell clustering of scRNA-seq data and to visualize clusters using the UMAP package (21). To define marker genes for clusters, clusters featuring similar marker genes were manually combined into one cell type, followed by the use of gene markers for known cell types to generate initial partitions of cells into broad cell clusters. Using the "FindAllMarkers" function, the differentially expressed mitochondrial genes in each cell type were identified. Differences associated with  $P < 0.05$  were considered significant.

### **Mapping of spatial transcriptomics metadata**

The spatial transcriptomics (ST) technique places histological tissue sections on ST slides, which consist of 1007 ST spots covering the slides. In addition, clustered ST spots were plotted onto hematoxylin and eosin (H&E) stained images with specific colors representing the respective clusters. We performed clustering by the UMAP method based on the morphology observed in the H&E-stained histological tissue sections.

### **Identification of Cluster-Specific Genes in Spatial Transcriptomics**

For each identified cluster, differentially expressed genes (DEGs) associated with all other spots were identified. A list of spatially clustered genes was first generated for all genes differentially expressed in the ST clusters ( $\log_{2}FC > 0.25$ , adjusted P-value  $< 0.05$ ).

## Single-cell trajectory analysis

The R package Monocle 3 was applied to align cells along the trajectory in pseudo-time (<https://cole-trapnell-lab.github.io/monocle3>). After clustering the cells using the above method, the dimensionality was reduced and the results were visualized using the UMAP method. Subsequently, cells were sorted according to their progression through the developmental program. monocle measured this progression in pseudo-time. In this study, single-cell trajectory analysis of cell subtypes was performed as needed.

## Functional enrichment analysis of cell clusters

Gene Ontology (GO) enrichment of cell clusters and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were used to determine the biological significance of each cell type. GO and KEGG pathway analysis was performed for marker genes for each cell subpopulation using the clusterProfiler package (22). Results associated with  $P < 0.05$  were considered significant.

## Analysis of intercellular communication

Intercellular communication analysis was performed using iTALK in the R package. Receptor-ligand interactions were determined using the STRING database of protein-protein interactions (23).

## Molecular docking of ligands and receptors

To clarify the target binding ability between ligand-receptor axes, molecular docking studies were performed using Hex 8.0.0 software (24). Docking models were visualized using Pymol software (25).

## Results

### Global single-cell and spatial landscapes of AD and healthy brains

The analytical flow of this study is shown in Figure 1A. We constructed a large-scale global single-cell landscape on AD brain tissue and healthy brain tissue. By cell clustering analysis, a total of 252 cell clusters were obtained and identified into 19 cell types based on known markers, including excitatory neurons (ExNeu), oligodendrocytes (Oli), inhibitory neurons (InNeu), microglia (Mic), pyramidal cells (PyrNeu), oligodendrocyte precursor cells (Opc), CD8<sup>+</sup>T cells (CD8.T), astrocytes (Ast), endothelial cells (En), CD4<sup>+</sup>T cells (CD4.T), macrophages (Mac), pericytes (Per), Schwann cells (Sch), Purkinje neurons (PurkinjeNeu), initial T cells (Naive.T),

ventricular meningeal cells (Ependymal), fibroblast-like cells (Fib\_ like), smooth muscle cells (SMC), and B cells (B) (Figure 1 B). Each cell type showed specific expression of markers for known cell types (Figure 1C). Subsequently, differential expression analysis was used to further explore the differentially expressed genes for each cell type in AD. Notably, there was significant dysregulation of mitochondrial gene expression in both excitatory and inhibitory neurons in AD compared to controls (Figure 1D), and there may be neuronal mitochondrial damage depletion-mediated cell death. Further by spatial transcriptome techniques, we could see a significant dysregulation of mitochondrial gene expression in AD relative to controls (Figure 1 E, F).

### **ExNeu\_PRKN\_VIRMA subpopulation progressively increases in abundance and reaches the highest percentage of excitatory neurons in AD progression**

Mitochondria are organelles essential for synaptic function, and their dysfunction is one of the early pathological features of AD. Moreover, there is growing evidence that mitochondrial defect is a key factor contributing to synaptic failure and degeneration in AD. Therefore, we extracted cells with dysregulated mitochondrial gene expression (excitatory and inhibitory neurons) for re-clustering. By analysis, a total of 16 subgroups of excitatory neuronal cells were obtained. Among them, the ExNeu\_PRKN\_VIRMA subpopulation had the highest percentage in AD patients (Figure 2A). Therefore, we explored the expression as well as co-expression of parkin RBR E3 ubiquitin protein ligase (PRKN) and VIRMA in the single cell profiles of ExNeu\_PRKN\_VIRMA subpopulation (Figure 2B). In addition, spatial transcriptome profiles of the ExNeu\_PRKN\_VIRMA subpopulation showed the expression of marker genes of excitatory neurons (*NRGN*), *PRKN* and *VIRMA* in control and AD, respectively. Compared to control, *NRGN*, *PRKN* and *VIRMA* possessed higher and more extensive expression in AD (Figure 2C). Notably, the abundance of ExNeu\_PRKN\_VIRMA subpopulation gradually increased with the progression of AD (Figure 2D). Furthermore, the proposed chronological values of excitatory neuron progression from Control to AD were mapped in the single-cell atlas by the proposed chronological analysis (Figure 2E), and the developmental trajectory of excitatory neurons was shown (Figure 2F), and it could be observed that the ExNeu\_PRKN\_VIRMA subpopulation was at the end of excitatory neuron development. Enrichment analysis showed that the dysregulated genes of ExNeu\_PRKN\_VIRMA subpopulation were significantly involved in BP such as mitochondrial to lysosomal translocation, mitochondrial

autophagy and pathways such as axon guidance, glutamatergic synapses, cell adhesion molecules, calcium signaling pathway, Wnt signaling pathway and Rap1 signaling pathway (Figure 2G). We can see that mitochondrial autophagy of ExNeu\_PRKN\_VIRMA is inhibited in the pathway map (Figure 2H).

### **Increased abundance of PRKN and VIRMA double-positive subpopulations were also found in inhibitory neurons in AD brains**

Similarly, five different cell subgroups were obtained by re-clustering the inhibitory neurons. Surprisingly, the subpopulation InNeu\_PRKN\_VIRMA, which is double positive for PRKN and VIRMA, was also found in inhibitory neurons, and again this subpopulation had the highest percentage in AD patients (Figure 3A). Subsequently, we explored the expression and co-expression of PRKN and VIRMA in the single-cell profiles of this subpopulation (Figure 3B). spatial transcriptome profiles of the InNeu\_PRKN\_VIRMA subpopulation showed that marker genes for inhibitory neurons *GAD1*, *PRKN* and *VIRMA* had higher and more widespread expression in AD compared to controls (Figure 3C). By cellular abundance analysis, we found that the abundance of ExNeu\_PRKN\_VIRMA subpopulation was likewise higher in AD (Figure 3D). The proposed chronological analysis showed that the cells of the InNeu\_PRKN\_VIRMA subpopulation of inhibitory neurons were partially in early development but mostly in late development during the development of AD (Figure 3E, F). Enrichment analysis showed that the InNeu\_PRKN\_VIRMA subpopulation's were significantly involved in BP such as positive regulation of mitochondrial autophagy by mitochondrial depolarization, regulation of mitochondrial autophagy and mitochondrial to lysosomal transport as well as axon guidance, glutamatergic synapses, cell adhesion molecules, Rap1 signaling pathway and cAMP signaling pathway (Figure 3G). In addition, we can see that mitochondrial autophagy of InNeu\_PRKN\_VIRMA is inhibited in the pathway map (Figure 3H).

### **VIRMA-promoted m6A methylation of PRKN mediates mitochondrial damage depletion contributing to a major component of the neuronal death ecotone**

Correlation analysis showed that the expression of VIRMA and PRKN were significantly positively correlated in excitatory and inhibitory neurons (Figure 4A, B). Not only that, the

abundance of ExNeu\_PRKN\_VIRMA and InNeu\_PRKN\_VIRMA subpopulations were also significantly positively correlated in AD patient samples (Figure 4C), thus, VIRMA may have a reciprocal relationship with PRKN. Sequence prediction by catRAPID revealed a binding region of VIRMA protein to the mRNA of PRKN (Figure 4D). Subsequent molecular docking confirmed the possibility of binding of VIRMA protein to the mRNA of PRKN (Figure 4E), suggesting that VIRMA plays an important role in the neuronal death by promoting high PRKN expression mediating mitochondrial damage through m6A methylation.

### **Mic\_PTPRG is significantly increased with amyloid beta precursor protein deposition in AD brain**

Twenty different cell subpopulations were obtained by re-clustering microglia (Figure 5A). Notably, the receptor protein tyrosine phosphatase (Ptpg-RPTP $\gamma$ ) encoded by PTPRG is predominantly expressed in the nervous system and has an important role in human diseases such as neuropsychiatric and behavioral disorders, central nervous system and inflammatory diseases. Therefore, we further explored the Mic\_PTPRG subpopulation. As shown in Figure 5B, the expression of PTPRG was mapped in a single-cell atlas of microglia. ST mapping revealed that *PTPRG* expression was dysregulated in AD compared to control (Figure 5C). In addition, Mic\_PTPRG subpopulation cells were also in higher abundance in AD (Figure 5D). Enrichment analysis revealed that the dysregulated genes in Mic\_PTPRG subpopulation cells were significantly involved in mitochondrial DNA replication regulation and autophagic cell death regulatory processes (Figure 5E). The proposed chronological analysis showed that Mic\_PTPRG subpopulation cells were at a late developmental stage in the progression of microglia to AD (Figure 5F,G).

### **Mic\_PTPRG communicates intercellularly with neurons based on ligand-receptor interaction pairs**

Compared to the control, the cellular abundance of the Mic\_PTPRG subpopulation with the PRKN and VIRMA double-positive subpopulations InNeu\_PRKN\_VIRMA and ExNeu\_PRKN\_VIRMA were both significantly increased in AD and both were at a late stage of cell development in the progression to AD. Preliminary analysis revealed extensive communication



between these subpopulations of cells (Figure 6A). Notably, both InNeu\_PRKN\_VIRMA and ExNeu\_PRKN\_VIRMA subpopulations were present in which CNTN4 was able to target the PTPRG of the Mic\_PTPRG subpopulation (Figure 6B). Subsequently, the expression of CNTN4 and co-expression with PRKN and VIRMA, respectively, were mapped in the cell profiles of InNeu\_PRKN\_VIRMA and ExNeu\_PRKN\_VIRMA subpopulations. It can be observed that CNTN4 was widely expressed in InNeu\_PRKN\_VIRMA and ExNeu\_PRKN\_VIRMA subpopulations (Figure 6C, D). In addition, spatial transcriptome profiling showed higher and more extensive expression of *CNTN4* and *PTPRG* in AD compared to controls (Figure 6E). This suggests that the Mic\_PTPRG subpopulation may communicate intercellularly with the InNeu\_PRKN\_VIRMA and ExNeu\_PRKN\_VIRMA subpopulations of neurons based on PTPRG-CNTN4.

### **Ectopic expression of microglia-derived PTPRG induces PRKN and VIRMA double-positive neuronal production**

Similarly, we observed that PTPRG was widely expressed in the InNeu\_PRKN\_VIRMA and ExNeu\_PRKN\_VIRMA subpopulations and co-expressed with PRKN and VIRMA (Figure 7A, B). Sequence prediction by catRAPID revealed a binding region of PTPRG protein to the mRNA of VIRMA (Figure 7C), and molecular docking confirmed the possibility of binding of PTPRG protein to the mRNA of VIRMA (Figure 7D). It is thus speculated that there may be ectopic expression of microglia-derived PTPRG, which induces the production of PRKN and VIRMA double-positive neurons.

### **Discussion**

Using the single-cell landscape constructed in this study, we found a significant dysregulation of mitochondrial gene expression in both excitatory and inhibitory neurons in AD compared to controls, and possible neuronal mitochondrial damage depletion-mediated cell death. A series of neuronal subpopulations were subsequently identified and validated in spatial histology. Among them, the ExNeu\_PRKN\_VIRMA subpopulation had the highest proportion in AD patients and progressively increased in abundance over the progression of AD. Intriguingly, a double positive subpopulation of PRKN and VIRMA was also found in inhibitory neurons, and its abundance also

increased progressively during the progression of AD. Various degrees of dysregulated mitochondrial gene expression were found in both ExNeu\_PRKN\_VIRMA and InNeu\_PRKN\_VIRMA neuronal subpopulations. Through further analysis, these neuronal subpopulations were found to be the main constituents contributing to the ecology of mitochondrial damage depletion in AD neurons with certain mitochondrial damage depletion as well as energy and nutrient metabolic imbalance that induces neuronal death.

Mitochondria are organelles essential for synaptic function, and mitochondrial dysfunction and synaptic failure are also characteristic early manifestations of pathology in the brain of AD patients (26). There is growing evidence that mitochondrial disorders are key factors contributing to synaptic failure and degeneration in AD (27, 28), and proteomic studies of synaptic vesicles in AD brain tissue have also highlighted mitochondrial dysfunction at synapses (29, 30). Significant changes in mitochondrial dynamics and organization, such as being elongated, enlarged and over fusion, also occur in different models of cellular senescence (31). Furthermore, it was shown that PRKN (parkin RBR E3 ubiquitin protein ligase) plays a key role in mitochondrial autophagy regulation and neuroprotection (32) and its overexpression inhibits extracellular mitochondrial release under basal and stress conditions (33). In the early and middle stages of AD, Parkin levels increased significantly and the recruitment to depolarized mitochondria increased, promoting mitochondrial autophagy and clearance of damaged mitochondria, but with disease progression, Parkin levels gradually decreased and eventually depleted, which caused a large accumulation of defective mitochondria and eventually affected neuronal function, leading to their death (34). PINK1 (PTEN-inducible kinase 1) recruits PRKN to depolarized mitochondria that ubiquitinates multiple target proteins on the outer mitochondrial membrane and subsequently promotes autophagic degradation of mitochondria (35, 36). In contrast, disruption of PINK1/Parkin signaling leads to impaired mitochondrial function and ultimately to neurodegenerative and neuroinflammatory processes (37). This suggests that PINK1-recruited PRKN can activate mitochondrial autophagy and mitotic clearance of damaged mitochondria and protect neurons.

However, in our study, none of these neuronal subpopulations expresses PINK1 or activates mitochondrial autophagy. It is possible that the progression of AD is accompanied by defective mitochondrial autophagy and consequent progressive depletion of PRKN, which in turn exacerbates the ecology of neuronal death. However, the mechanism of PRKN depletion remains unexplored

due to the uncertainty of AD progression and changes in molecular abundance. As we captured a large subpopulation of PRKN transcript-positive neurons in AD patients, it provides us with the conditions to observe and explore the molecular mechanism of PRKN depletion at single-cell resolution. In the PRKN transcript-positive neuronal subpopulations, PRKN and the m6A methyltransferase VIRMA were co-expressed in the ExNeu and InNeu subpopulations, suggesting a potential association between the two. Among them, VIRMA is a related gene encoding a Vir-like m6A methyltransferase. In contrast, m6-methyladenosine (m6A) is the most common chemical epigenetic modification in mRNA post-transcriptional modifications, including methylation, demethylation and recognition (38). In the healthy brain, m6A maintains a variety of developmental and physiological processes such as neurogenesis, axonal growth, synaptic plasticity, circadian rhythms, cognitive function, and stress response (39). Aberrant expression of m6A-related proteins may occur in the nervous system, thereby affecting neurogenesis, brain volume, learning memory, memory formation, and consolidation (40). By constructing a molecular docking model, we identified the binding potential of VIRMA to PRKN. This suggests that VIRMA may promote the degradation of PRKN transcripts by increasing their m6A methylation modification levels to inhibit their translation.

Multiple studies have collectively shown that microglia are critical for neuronal homeostasis and health (41). In the adult brain, microglia have multiple functions, including monitoring changes in neuronal activity, regulating learning and memory, and acting as local phagocytosis and injury sensors in the brain parenchyma (42-48). Among them, mostly microglia-neuron interactions are mediated by cell-cell signaling pathways, including purinergic signaling pathways, cytokines, neurotransmitters and neuropeptides (49). Previous studies have shown that accumulation of pathological A $\beta$  or Tau at the synapse can upregulate C1q in microglia and promote complement activation and subsequent microglia phagocytosis at the synapse (50-53). Blocking activation of the classical complement cascade pathway in mouse models of AD with genetic or antibody-based approaches has been shown to protect synapses from synaptic loss, dysfunction, and memory loss (54), suggesting that the microglia-synaptic pathway may be a potential therapeutic target.

Through intercellular communication analysis, we identified that Mic\_PTPRG, a subpopulation of microglia also progressively increased in AD progression, can anchor target and communicate with PRKN and VIRMA dual positive neuronal subpopulations based on ligand-

receptor interaction pairs, which in turn promotes ectopic expression of PTPRG in neurons, while aberrantly expressed PTPRG enhances the RNA of VIRMA stability. Notably, the receptor protein tyrosine phosphatase (Ptp<sup>rg</sup>-RPTP $\gamma$ ) encoded by PTPRG is predominantly expressed in the nervous system and has an important role in human diseases such as neuropsychiatric and behavioral disorders, central nervous system and inflammatory diseases (55), and is a potential risk gene for late-onset dementia (56). PTPRG mediates cell adhesion and signaling during development (57), which is usually upregulated during neuroinflammation (58) while microglia are specialized phagocytes that reside in tissues for long periods of time and investigate and rapidly respond to changes in their microenvironment (59). It is thus hypothesized that the microglia subpopulation Mic\_PTPRG may arise due to microglial role in phagocytosis and removal of over-deposited APP from the patient's brain.

Given certain limitations, our results should be interpreted with caution. Given our results were obtained exclusively by bioinformatics analysis, they should be validated and extended in a functional biochemical study.

## Conclusion

Our study shows that excessive deposition of amyloid  $\beta$  precursor protein can induce PTPRG-positive microglia subpopulations to produce and anchor target neurons via intercellular ligand-receptor interactions communication, causing ectopic expression of PTPRG in neurons. PTPRG in neurons can bind and upregulate the expression of m6A methyltransferase VIRMA, which in turn increases the level of m6A modification of PRKN transcripts and decreases their RNA stability and translational activity. Expression of repressed PRKN causes a clear block in neuronal cell injury depleting mitochondria and builds up, which in turn reprograms neuronal energy and nutrient metabolic pathways and mediates neuronal death under AD progression.

## Data availability statement

The datasets supporting the conclusions of this article are available in the Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)).

## Ethics Approval and Informed Consent

The Ethics Committee from the Second Affiliated Hospital of Guangxi Medical University waived the requirements for ethics approval because our analyses were based entirely on publicly available

data from studies that had been approved by the relevant ethics committees at the research institutions involved.

**Acknowledgement:** This study was supported by the National Natural Science Foundation of China (82060210), the Nanning Excellent Young Scientist Program and the Guangxi Beibu Gulf Economic Zone Major Talent Program (RC20190103).

## Disclosure

The authors have no potential conflicts of interest to declare.

## References

1. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. *Cell*. 2012;148(6):1204-22.
2. Kukull WA, Bowen JD. Dementia epidemiology. *Med Clin North Am*. 2002;86(3):573-90.
3. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. *Dialogues Clin Neurosci*. 2009;11(2):111-28.
4. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. *Int J Nanomedicine*. 2019;14:5541-54.
5. Gallardo G, Holtzman DM. Amyloid-beta and Tau at the Crossroads of Alzheimer's Disease. *Adv Exp Med Biol*. 2019;1184:187-203.
6. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. *Cold Spring Harb Perspect Med*. 2011;1(1):a006189.
7. Donev R, Kolev M, Millet B, Thome J. Neuronal death in Alzheimer's disease and therapeutic opportunities. *J Cell Mol Med*. 2009;13(11-12):4329-48.
8. Cardanho-Ramos C, Morais VA. Mitochondrial Biogenesis in Neurons: How and Where. *Int J Mol Sci*. 2021;22(23).
9. Westermann B. Bioenergetic role of mitochondrial fusion and fission. *Biochim Biophys Acta*. 2012;1817(10):1833-8.
10. Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. *Cell*. 2007;130(3):548-62.
11. Westermann B. Molecular machinery of mitochondrial fusion and fission. *J Biol Chem*. 2008;283(20):13501-5.
12. Chen H, Chan DC. Mitochondrial dynamics--fusion, fission, movement, and mitophagy--in neurodegenerative diseases. *Hum Mol Genet*. 2009;18(R2):R169-76.
13. Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, et al. Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. *Int J Clin Exp Pathol*. 2010;3(6):570-81.
14. Perez Ortiz JM, Swerdlow RH. Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities. *Br J Pharmacol*. 2019;176(18):3489-507.
15. Eze UC, Bhaduri A, Haeussler M, Nowakowski TJ, Kriegstein AR. Single-cell atlas of early human brain development highlights heterogeneity of human neuroepithelial cells and early radial glia. *Nat Neurosci*. 2021;24(4):584-94.
16. Kanton S, Boyle MJ, He Z, Santel M, Weigert A, Sanchis-Calleja F, et al. Organoid single-cell genomic atlas uncovers human-specific features of brain development. *Nature*. 2019;574(7778):418-22.

17. Lau SF, Cao H, Fu AKY, Ip NY. Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2020;117(41):25800-9.
18. Navarro JF, Croteau DL, Jurek A, Andrusivova Z, Yang B, Wang Y, et al. Spatial Transcriptomics Reveals Genes Associated with Dysregulated Mitochondrial Functions and Stress Signaling in Alzheimer Disease. *iScience*. 2020;23(10):101556.
19. Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, et al. Single-cell transcriptomic analysis of Alzheimer's disease. *Nature*. 2019;570(7761):332-7.
20. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, et al. Comprehensive Integration of Single-Cell Data. *Cell*. 2019;177(7):1888-902 e21.
21. Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG, et al. Dimensionality reduction for visualizing single-cell data using UMAP. *Nat Biotechnol*. 2018.
22. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS*. 2012;16(5):284-7.
23. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res*. 2017;45(D1):D362-D8.
24. Macindoe G, Mavridis L, Venkatraman V, Devignes MD, Ritchie DW. HexServer: an FFT-based protein docking server powered by graphics processors. *Nucleic Acids Res*. 2010;38(Web Server issue):W445-9.
25. Mooers BHM. Shortcuts for faster image creation in PyMOL. *Protein Sci*. 2020;29(1):268-76.
26. Du F, Yu Q, Yan S, Hu G, Lue LF, Walker DG, et al. PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease. *Brain*. 2017;140(12):3233-51.
27. Cai Q, Tammineni P. Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer's Disease. *J Alzheimers Dis*. 2017;57(4):1087-103.
28. Guo L, Tian J, Du H. Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease. *J Alzheimers Dis*. 2017;57(4):1071-86.
29. Hesse R, Hurtado ML, Jackson RJ, Eaton SL, Herrmann AG, Colom-Cadena M, et al. Comparative profiling of the synaptic proteome from Alzheimer's disease patients with focus on the APOE genotype. *Acta Neuropathol Commun*. 2019;7(1):214.
30. Gyorffy BA, Toth V, Torok G, Gulyassy P, Kovacs RA, Vadaszi H, et al. Synaptic mitochondrial dysfunction and septin accumulation are linked to complement-mediated synapse loss in an Alzheimer's disease animal model. *Cell Mol Life Sci*. 2020;77(24):5243-58.
31. Martini H, Passos JF. Cellular senescence: all roads lead to mitochondria. *FEBS J*. 2022.
32. Murillo-Gonzalez FE, Garcia-Aguilar R, Vega L, Elizondo G. Regulation of Parkin expression as the key balance between neural survival and cancer cell death. *Biochem Pharmacol*. 2021;190:114650.
33. Choong CJ, Okuno T, Ikenaka K, Baba K, Hayakawa H, Koike M, et al. Alternative mitochondrial quality control mediated by extracellular release. *Autophagy*. 2021;17(10):2962-74.
34. Ye X, Sun X, Starovoytov V, Cai Q. Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer's disease patient brains. *Hum Mol Genet*. 2015;24(10):2938-51.
35. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol*. 2010;8(1):e1000298.
36. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat Cell Biol*. 2010;12(2):119-31.

37. Quinn PMJ, Moreira PI, Ambrosio AF, Alves CH. PINK1/PARKIN signalling in neurodegeneration and neuroinflammation. *Acta Neuropathol Commun.* 2020;8(1):189.
38. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell.* 2012;149(7):1635-46.
39. Chokkalla AK, Mehta SL, Vemuganti R. Epitranscriptomic regulation by m(6)A RNA methylation in brain development and diseases. *J Cereb Blood Flow Metab.* 2020;40(12):2331-49.
40. Zhang N, Ding C, Zuo Y, Peng Y, Zuo L. N6-methyladenosine and Neurological Diseases. *Mol Neurobiol.* 2022;59(3):1925-37.
41. Bartels T, De Schepper S, Hong S. Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases. *Science.* 2020;370(6512):66-9.
42. Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, 3rd, Lafaille JJ, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. *Cell.* 2013;155(7):1596-609.
43. Stowell RD, Sipe GO, Dawes RP, Batchelor HN, Lordy KA, Whitelaw BS, et al. Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex. *Nat Neurosci.* 2019;22(11):1782-92.
44. Liu YU, Ying Y, Li Y, Eyo UB, Chen T, Zheng J, et al. Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling. *Nat Neurosci.* 2019;22(11):1771-81.
45. Bernier LP, York EM, Kamyabi A, Choi HB, Weilingner NL, MacVicar BA. Microglial metabolic flexibility supports immune surveillance of the brain parenchyma. *Nat Commun.* 2020;11(1):1559.
46. Wang C, Yue H, Hu Z, Shen Y, Ma J, Li J, et al. Microglia mediate forgetting via complement-dependent synaptic elimination. *Science.* 2020;367(6478):688-94.
47. Nguyen PT, Dorman LC, Pan S, Vainchtein ID, Han RT, Nakao-Inoue H, et al. Microglial Remodeling of the Extracellular Matrix Promotes Synapse Plasticity. *Cell.* 2020;182(2):388-403 e15.
48. Cserep C, Posfai B, Lenart N, Fekete R, Laszlo ZI, Lele Z, et al. Microglia monitor and protect neuronal function through specialized somatic purinergic junctions. *Science.* 2020;367(6477):528-37.
49. De Schepper S, Crowley G, Hong S. Understanding microglial diversity and implications for neuronal function in health and disease. *Dev Neurobiol.* 2021;81(5):507-23.
50. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science.* 2016;352(6286):712-6.
51. Dejanovic B, Huntley MA, De Maziere A, Meilandt WJ, Wu T, Srinivasan K, et al. Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies. *Neuron.* 2018;100(6):1322-36 e7.
52. Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, et al. Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer's Disease. *Neuron.* 2018;100(6):1337-53 e5.
53. Wu T, Dejanovic B, Gandham VD, Gogineni A, Edmonds R, Schauer S, et al. Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. *Cell Rep.* 2019;28(8):2111-23 e6.
54. Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. *Sci Transl Med.* 2017;9(392).
55. Boni C, Laudanna C, Sorio C. A Comprehensive Review of Receptor-Type Tyrosine-Protein Phosphatase Gamma (PTPRG) Role in Health and Non-Neoplastic Disease. *Biomolecules.* 2022;12(1).
56. Herold C, Hooli BV, Mullin K, Liu T, Roehr JT, Mattheisen M, et al. Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6,




PTPRG, and PDCL3. Mol Psychiatry. 2016;21(11):1608-12.

57. Bouyain S, Watkins DJ. The protein tyrosine phosphatases PTPRZ and PTPRG bind to distinct members of the contactin family of neural recognition molecules. Proc Natl Acad Sci U S A. 2010;107(6):2443-8.

58. Lorenzetto E, Moratti E, Vezalini M, Harroch S, Sorio C, Buffelli M. Distribution of different isoforms of receptor protein tyrosine phosphatase gamma (Ptprg-RTP gamma) in adult mouse brain: upregulation during neuroinflammation. Brain Struct Funct. 2014;219(3):875-90.

59. Suss P, Schlachetzki JCM. Microglia in Alzheimer's Disease. Curr Alzheimer Res. 2020;17(1):29-43.

## Figure legend




**Figure 1. Single-cell transcriptome and spatial transcriptome construction of global single-cell and spatial landscapes of AD and healthy brains. A. Flow chart of this study. B. Single-cell atlas**




mapping cell types. C. Vesicle map showing global brain tissue single-cell each cell type corresponding to CellMarker. D. Multi-group volcano map showing expression differences of each cell type in AD relative to healthy donor brain cells. E. AD mouse model section HE staining- ST mapping- ST UMAP- Mitochondrial gene expression. F. Healthy mouse model section HE staining- ST mapping- ST UMAP- Mitochondrial gene expression.



excitatory neuron subpopulations in AD-Control. E. Single-cell atlas mapping the proposed chronological values of excitatory neuron progression from Control to AD. F. Single-cell atlas-pie chart mapping the proposed chronological trajectory of excitatory neuron progression from Control to AD, with the pie chart representing the proportion of AD and Control in each subpopulation. G. Clustering-bubble chart demonstrating biological functions and pathways significantly activated by ExNeu\_PRKN\_VIRMA subpopulation genes. H. Pathway Map graph demonstrating the suppression of mitochondrial autophagy in ExNeu\_PRKN\_VIRMA.




**Figure 3. Role of inhibitory neuron subpopulations in the development of AD.** A. Single-cell atlas mapping inhibitory neuron subpopulations. B. Single-cell atlas showing the expression of PRKN and VIRMA, co-expression of PRKN and VIRMA. C. ST atlas showing the expression of marker genes *GADI*, *PRKN* and *VIRMA* in inhibitory neuron subpopulations. D. Dotted line graph showing proportion of inhibitory neuron subpopulations in AD-Control. E. Single-cell atlas mapping the proposed chronological values of inhibitory neuron progression from Control to AD. F. Single-cell atlas-pie chart mapping the proposed chronological trajectory of inhibitory neuron progression from Control to AD, with the pie chart representing the proportion of AD and Control in each subpopulation. G. Clustering-bubble chart demonstrating biological functions and pathways significantly activated by InNeu\_PRKN\_VIRMA subpopulation genes. H. Pathway Map graph demonstrating the suppression of mitochondrial autophagy in InNeu\_PRKN\_VIRMA.




**Figure 4. Validation of VIRMA and PRKN interactions.** A. Correlation scatter plot demonstrating the correlation of VIRMA and PRKN expression in ExNeu. B. Correlation scatter plot demonstrating the correlation of VIRMA and PRKN expression in InNeu. C. Correlation scatter plot demonstrating the correlation of ExNeu\_PRKN\_VIRMA and InNeu\_PRKN\_ in patient samples. VIRMA abundance correlation. D. Heat map demonstrating the mRNA binding potential of VIRMA protein and PRKN. E. Molecular docking model demonstrating the binding sites of



VIRMA protein and mRNA of PRKN.




**Figure 5. Role played by microglia subpopulations in AD development.** A. Single-cell atlas mapping microglia subpopulations. B. Single-cell atlas mapping PTPRG expression showing microglia subpopulations. C. Vacancy mapping showing PTPRG expression in microglia subpopulations. D. Dotted line graph showing the proportion of microglia subpopulations in AD-Control. E. Clustered-bubble graph showing biological functions and pathways of significant gene activation in Mic\_PTPRG subpopulation. F. Single-cell atlas mapping the proposed chronological values of microglia progression from Control to AD. G. Single-cell atlas-pie chart mapping the proposed chronological trajectory of microglia progression from Control to AD, with the pie chart representing the proportion of AD and Control in each subpopulation.



**Figure 6. Verification of the existence of cellular communication between the Mic\_PTPRG subpopulation and the PRKN and VIRMA double-positive subpopulations. A.** Vesicular circular network diagram demonstrating the communication profile between microglia and VIRMA and PRKN double-positive neuronal cells (ExNeu\_PRKN\_VIRMA and InNeu\_PRKN\_VIRMA) in AD brain tissue. **B.** Reciprocal circular network plot demonstrating the communication events



between Mic\_PTPRG and VIRMA and PRKN dual positive neuronal cells (i.e. ExNeu\_PRKN\_VIRMA and InNeu\_PRKN\_VIRMA) in AD brain tissue. C. Single-cell atlas demonstrating CNTN4 expression in ExNeu\_PRKN\_VIRMA and CNTN4 and PRKN\_VIRMA co-expression. D. Single-cell profiles demonstrating CNTN4 expression in InNeu\_PRKN\_VIRMA and co-expression of CNTN4 and PRKN\_VIRMA. E. ST atlas demonstrating *CNTN4* and *PTPRG* expression.



**Figure 7. Validation of PTPRG binding to VIRMA ligand-receptor.** A. Single-cell mapping demonstrating the expression of PTPRG in ExNeu\_PRKN\_VIRMA and co-expression of PTPRG and PRKN\_VIRMA. B. Single-cell mapping demonstrating the expression of PTPRG in InNeu\_PRKN\_VIRMA and co-expression of PTPRG and PRKN\_VIRMA. C. Heat map demonstrating the mRNA binding potential of PTPRG protein and VIRMA. D. Molecular docking model demonstrating the binding sites of PTPRG protein and mRNA of VIRMA.